A new analysis of orphan drug approvals across six global regulatory regions highlights significant delays in access to innovative therapies for people living with rare diseases. The study, conducted by the International Rare Diseases Research Consortium (IRDiRC) Regulatory Science Committee (RSC), examined all new non-oncology orphan medicines approved between 2021 and 2022 and found substantial variation in approval timelines despite relying on highly similar evidence packages.
Key Findings
- Approval delays average 3 years: Time between first and subsequent approvals varied widely, with an average delay of three years by the time a medicine reached its third to sixth approval.
- Global reach, but limited submissions: While 99% of orphan drugs were approved in two or more regions, very few were submitted broadly across all major regulatory jurisdictions.
- Consistent evidence across regions: Most products (69%) were authorized using the same or highly similar evidence, showing alignment in regulatory expectations.
- Lean evidence requirements: A single adequate and well-controlled study, supported by confirmatory evidence, was sufficient for most regulatory authorizations.
- Opportunity for acceleration: The findings suggest that collaborative regulatory programs—including shared reviews or reliance models—could significantly shorten global approval timelines.
Why This Matters
Rare diseases affect over 300 million people worldwide, yet only a small fraction of these thousands of conditions have an approved treatment. Because patient populations are small and geographically dispersed, developing orphan medicines requires multinational clinical trials and coordinated regulatory pathways.
However, the study shows that even after a therapy is approved in one region, patients elsewhere may wait years for access—despite regulators largely accepting the same evidence. This bottleneck highlights the need for improved international coordination.
About the Study
IRDiRC’s Regulatory Science Committee conducted a retrospective review of publicly available data on 53 orphan products approved across the United States, European Union, Japan, Canada, Australia, and Brazil. The goal: to understand how evidence requirements and approval timelines differ, and to identify ways to minimize delays.
The analysis revealed a high degree of consistency in the scientific evidence accepted by regulators—indicating strong potential for global collaborative review approaches to benefit both developers and patients.
Access the full publication: https://pubmed.ncbi.nlm.nih.gov/41207528/